EICHORPublic-registry site landscape for NCT07752108, “A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis”, a Palmoplantar Psoriasis study sponsored by Takeda. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07752108 (registry record) |
| Study title | A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis |
| Official title | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Moderate-to-severe Non-pustular Palmoplantar Psoriasis (PPPsO) |
| Sponsor | Takeda |
| Condition(s) | Palmoplantar Psoriasis |
| Phase | PHASE3 |
| Listed sites | 0 |
| Intervention(s) | Zasocitinib |
Patient-friendly overview of this study: eichor.com/study/NCT07752108.
Eichor generates a preliminary site-risk snapshot for NCT07752108 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
